William I Bensinger1. 1. Division of Clinical Research, The Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, Washington, USA. wbensing@fhcrc.org
Abstract
PURPOSE OF REVIEW: Peripheral blood stem cells (PBSCs) have been widely adopted as a source of stem cells for allogeneic transplantation, although controversy remains regarding their role compared to the use of bone marrow. RECENT FINDINGS: Ten-year follow-up has been reported from several large randomized trials and a recently completed trial using unrelated donor stem cells has been reported. In addition, two meta-analyses have been reported from the findings of a number of randomized studies. Several studies indicate that PBSCs confer survival advantages over bone marrow with matched sibling donors for most disease categories except where the risks of disease recurrence within the first year are low, but with the extra risk of more chronic graft-versus-host disease (GVHD). Using PBSCs from unrelated donors does not appear to be more beneficial than bone marrow, but with early follow-up. New strategies for rapid mobilization of PBSCs from normal donors using plerixafor have been reported. Early studies suggest that filgrastim-stimulated bone marrow may confer some of the advantages of PBSCs without the risks of chronic GVHD. SUMMARY: PBSCs are a preferred source of stem cells for many types of allogeneic transplant, in which matched related donors are available. Whether the same benefits accrue from unrelated donors will require further follow-up.
PURPOSE OF REVIEW: Peripheral blood stem cells (PBSCs) have been widely adopted as a source of stem cells for allogeneic transplantation, although controversy remains regarding their role compared to the use of bone marrow. RECENT FINDINGS: Ten-year follow-up has been reported from several large randomized trials and a recently completed trial using unrelated donor stem cells has been reported. In addition, two meta-analyses have been reported from the findings of a number of randomized studies. Several studies indicate that PBSCs confer survival advantages over bone marrow with matched sibling donors for most disease categories except where the risks of disease recurrence within the first year are low, but with the extra risk of more chronic graft-versus-host disease (GVHD). Using PBSCs from unrelated donors does not appear to be more beneficial than bone marrow, but with early follow-up. New strategies for rapid mobilization of PBSCs from normal donors using plerixafor have been reported. Early studies suggest that filgrastim-stimulated bone marrow may confer some of the advantages of PBSCs without the risks of chronic GVHD. SUMMARY: PBSCs are a preferred source of stem cells for many types of allogeneic transplant, in which matched related donors are available. Whether the same benefits accrue from unrelated donors will require further follow-up.
Authors: A C Vigorito; J F Marques Júnior; F J Aranha; G B Oliveira; E C Miranda; C A De Souza Journal: Haematologica Date: 2001-06 Impact factor: 9.941
Authors: Stephen Couban; David R Simpson; Michael J Barnett; Christopher Bredeson; Lothar Hubesch; Kang Howson-Jan; Tsiporah B Shore; Irwin R Walker; Peter Browett; Hans A Messner; Tony Panzarella; Jeffrey H Lipton Journal: Blood Date: 2002-09-01 Impact factor: 22.113
Authors: R Powles; J Mehta; S Kulkarni; J Treleaven; B Millar; J Marsden; V Shepherd; A Rowland; B Sirohi; D Tait; C Horton; S Long; S Singhal Journal: Lancet Date: 2000-04-08 Impact factor: 79.321
Authors: J S Serody; S D Sparks; Y Lin; E J Capel; S H Bigelow; S L Kirby; D A Gabriel; J M Wiley; M E Brecher; M J Schell; J Folds; T C Shea Journal: Biol Blood Marrow Transplant Date: 2000 Impact factor: 5.742
Authors: S Couban; H A Messner; P Andreou; B Egan; S Price; L Tinker; J Meharchand; D L Forrest; J Lipton Journal: Biol Blood Marrow Transplant Date: 2000 Impact factor: 5.742
Authors: R E Champlin; N Schmitz; M M Horowitz; B Chapuis; R Chopra; J J Cornelissen; R P Gale; J M Goldman; F R Loberiza; B Hertenstein; J P Klein; E Montserrat; M J Zhang; O Ringdén; S C Tomany; P A Rowlings; M E Van Hoef; A Gratwohl Journal: Blood Date: 2000-06-15 Impact factor: 22.113
Authors: W I Bensinger; P J Martin; B Storer; R Clift; S J Forman; R Negrin; A Kashyap; M E Flowers; K Lilleby; T R Chauncey; R Storb; F R Appelbaum Journal: N Engl J Med Date: 2001-01-18 Impact factor: 91.245
Authors: Norbert Schmitz; Meral Beksac; Dirk Hasenclever; Andrea Bacigalupo; Tapani Ruutu; Arnon Nagler; Eliane Gluckman; Nigel Russell; Jane F Apperley; Norbert C Gorin; Jeff Szer; Ken Bradstock; Agnes Buzyn; Peter Clark; Keith Borkett; Alois Gratwohl Journal: Blood Date: 2002-08-01 Impact factor: 22.113
Authors: C E Bunse; S Tischer; J Lahrberg; M Oelke; C Figueiredo; R Blasczyk; B Eiz-Vesper Journal: Clin Exp Immunol Date: 2016-05-13 Impact factor: 4.330
Authors: Bronwen E Shaw; Antonio Martin Jimenez-Jimenez; Linda J Burns; Brent R Logan; Farhad Khimani; Brian C Shaffer; Nirav N Shah; Alisha Mussetter; Xiao-Ying Tang; John M McCarty; Asif Alavi; Nosha Farhadfar; Katarzyna Jamieson; Nancy M Hardy; Hannah Choe; Richard F Ambinder; Claudio Anasetti; Miguel-Angel Perales; Stephen R Spellman; Alan Howard; Krishna V Komanduri; Leo Luznik; Maxim Norkin; Joseph A Pidala; Voravit Ratanatharathorn; Dennis L Confer; Steven M Devine; Mary M Horowitz; Javier Bolaños-Meade Journal: J Clin Oncol Date: 2021-04-27 Impact factor: 50.717
Authors: Oriana Miltiadous; Nicholas R Waters; Hana Andrlová; Anqi Dai; Chi L Nguyen; Marina Burgos da Silva; Sarah Lindner; John Slingerland; Paul Giardina; Annelie Clurman; Gabriel K Armijo; Antonio L C Gomes; Madhavi Lakkaraja; Peter Maslak; Michael Scordo; Roni Shouval; Anna Staffas; Richard O'Reilly; Ying Taur; Susan Prockop; Jaap Jan Boelens; Sergio Giralt; Miguel-Angel Perales; Sean M Devlin; Jonathan U Peled; Kate A Markey; Marcel R M van den Brink Journal: Blood Date: 2022-05-05 Impact factor: 25.476